Welcome to our dedicated page for aTyr Pharma SEC filings (Ticker: LIFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating cash-runway figures, pipeline updates, or patent disclosures in aTyr Pharma’s SEC documents can feel like decoding an advanced biology textbook. Each 10-K details physiocrine biology breakthroughs, while every 8-K announces pivotal clinical data that may move the share price overnight. If you have ever searched for aTyr Pharma SEC filings explained simply, you know the challenge.
Stock Titan eliminates the guesswork. Our AI parses every aTyr Pharma annual report 10-K simplified, extracts R&D spend, and flags risks in seconds. Need the latest aTyr Pharma quarterly earnings report 10-Q filing? We publish it the moment it hits EDGAR and provide side-by-side trend analysis. Real-time alerts surface aTyr Pharma Form 4 insider transactions real-time so you can monitor aTyr Pharma executive stock transactions Form 4 before the market reacts. From aTyr Pharma 8-K material events explained to aTyr Pharma proxy statement executive compensation, every filing is paired with AI-powered summaries that translate clinical jargon into clear insights.
Use these insights to:
- Track trial milestones without combing through hundreds of pages
- Compare quarter-over-quarter R&D trends via our aTyr Pharma earnings report filing analysis
- Spot sentiment shifts with aTyr Pharma insider trading Form 4 transactions
aTyr Pharma (Nasdaq: LIFE) filed Amendment No. 1 to its Form 8-K dated 7 Aug 2025 solely to correct an EDGAR header miscoding. The original report was inadvertently tagged as Item 2.06 (Material Impairments); the amendment re-submits the document under the proper Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits). All narrative content and exhibits are unchanged. Exhibit 99.1 remains the press release announcing financial results for the quarter ended 30 Jun 2025, and Exhibit 104 is the Inline XBRL cover data file. Because the earnings release is furnished—not filed—it is excluded from liability under Section 18 and from incorporation by reference unless expressly cited. No operational, financial, or strategic information has been modified; the amendment is purely administrative and carries no impact on previously disclosed results or guidance.
On 7 Aug 2025, aTyr Pharma (symbol: LIFE) filed a Form S-8 to register 5.3 million additional common shares for employee equity compensation.
- 2015 Stock Option & Incentive Plan: 5.0 m new shares, reflecting an amendment approved by shareholders on 1 May 2025.
- 2022 Inducement Plan: 0.3 m new shares, bringing the plan’s total to 0.6 m shares after Compensation Committee approval on 21 Mar 2025.
The filing is made under Securities Act Rule S-8, which allows automatic registration of shares issued through benefit plans; no immediate capital is raised. The company classifies itself as a non-accelerated filer and smaller reporting company. Key exhibits include its amended certificate, bylaws, legal opinion, auditor consent, and updated plan documents. Investors should note the incremental dilution risk from future option exercises and inducement grants, balanced against the need to attract and retain talent in a competitive biotech labor market.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
